US Pfizer confirms strong long-term immune effect of corona vaccine 12-15 years old

The US Pfizer announced on the 22nd that it has confirmed a strong long-term immune effect in a late-stage clinical trial (clinical trial) targeting 12 to 15 years old with respect to the new coronavirus vaccine jointly developed with Germany’s Biontech. bottom.

According to Pfizer, the efficacy rate was 100% even more than 4 months after the second vaccination.

The US Food and Drug Administration (FDA) approved an emergency permit in May for Pfizer vaccines for ages 12-15.

Pfizer Biontech will apply for formal approval for a 30 microgram dose of vaccination for people over the age of 12. The FDA officially approved vaccination for people over the age of 16 in August.

Recent Posts

China is working toward the release of oil reserves

A spokesman for China's State Administration of Grain and Food and Stockpiling said on the…

3 weeks ago

Amazon to stop accepting UK-issued Visa cards from next year announced on the 17th that it will stop accepting credit cards for visas issued…

3 weeks ago

Yuanhao Future CFO Luo Rong joins Baidu as CFO of Baidu Group

Baidu reported that the company issued a letter to all employees, announcing that Julius has…

1 month ago

SAIC Volkswagen plunged 15% in August!

Different from the popularity of Japanese cars in the country, the Volkswagen among German cars…

3 months ago

Huawei says 6G is expected to be put on the market around 2030

According to Huawei's voice community news, Huawei's rotating chairman Xu Zhijun stated in his preface…

3 months ago

This website uses cookies.